



**STATE OF HAWAII
DEPARTMENT OF HEALTH**

P. O. Box 3378
Honolulu, HI 96801-3378
doh.testimony@doh.hawaii.gov

**Testimony COMMENTING on HB 2102 HD1
RELATING TO HEMP PRODUCTS**

REPRESENTATIVE SYLVIA LUKE, CHAIR
HOUSE COMMITTEE ON FINANCE

Hearing Date: 2/19/2020

Room Number: 308

1 **Fiscal Implications:** This measure may impact the priorities identified in the Governor's
2 Executive Budget Request for the Department of Health's (Department) appropriations and
3 personnel priorities.

4 **Department Testimony:** The Department appreciates the opportunity to provide comments on
5 this measure.

6 This measure was amended, in part, to allow the Department to adopt rules, and interim rules, to
7 create a regulatory framework for the processing of hemp into hemp products that include, but
8 not limited to, the inspection, sampling, contaminant testing, lab certification, record keeping
9 requirements, establishing fees for application, disposal of violative hemp products, penalties and
10 other rules necessary to carry out this part.

11 The Department appreciates the inclusion of these amendments as it will allow a legal pathway
12 for local hemp products and out of state hemp product to be sold in Hawaii.

13 The Department respectfully requests the committee consider the following amendments to the
14 measure to ensure that the rulemaking process and regulatory oversight by the Department can
15 be met given the appropriate financial resources.

16 **Offered Amendments:**

17 NEW SECTION - Hawaii hemp processing special fund; established.

1 (a) There is established within the state treasury the Hawaii hemp processing special fund into
2 which shall be deposited:

3 (1) Appropriations made by the legislature to the special fund;

4 (2) Any income and capital gains earned by the fund; and

5 (3) Any fees or fines collected by the department pursuant to this part.

6 (b) Moneys in the Hawaii hemp processing special fund shall be used by the department
7 for the following purposes:

8 (1) To establish and regulate a system of registering hemp processors in the State;

9 (2) To fund positions and operating costs authorized by the legislature;

10 (3) For any other expenditure necessary, consistent with this part, to implement the
11 Hawaii hemp processing program."

12 NEW SECTION - . There is appropriated out of the general fund the sum of \$288,144 or
13 so much thereof as may be necessary for fiscal year 2020—2021, and the same sum or so much
14 as may be necessary for fiscal year 2021—2022 to be allocated as follows:

15 (1) \$288,144 for the establishment of three (3 FTE) Food Safety Specialist positions; one
16 (1 FTE) office assistant position; and one (1 FTE) accountant position to be expended
17 by the department of health.

18 Thank you for the opportunity to testify on this measure.

February 18, 2020

To: Representative Sylvia Luke, Chair
Representative Ty. J.K. Cullen, Vice Chair
Members of the House Committee on Finance

From: Maggie Cole, Pan Pacific Ventures

Re: TESTIMONY IN SUPPORT OF HB2102 HD1

RELATING TO HEMP PRODUCTS

As a state-licensed hemp producer dedicated to the production of quality-assured, hemp-derived consumer products made in Hawai'i, PPV strongly **supports** the key provisions contained within HB 2102 HD1, which would help to foster the development of an economically viable hemp industry in Hawai'i while safeguarding the public and affordably serving strong consumer demand for safe, affordable and accurately labeled products.

Cannabidiol (CBD) products that are produced by indoor cannabis producers are typically expensive because they are produced in highly controlled facilities that are very costly to operate. By contrast, CBD derived from industrial hemp, which is grown outdoors on a large scale, can be produced far more cheaply. PPV estimates that CBD derived from field grown industrial hemp can be produced at 1/10th the cost of CBD derived from cannabis cultivated in highly controlled indoor facilities.

That said, industrial hemp derived CBD is far more susceptible to contamination than cannabis derived CBD grown in controlled indoor facilities. As 'bioaccumulators', hemp plants commonly absorb and store soil impurities such as heavy metals. These impurities often find their way into hemp-derived consumer products. Furthermore, plants cultivated in large outdoor plots, as industrial hemp commonly is, are frequently exposed to pathogenic microbes and insect pests, and therefore demand the use of fungicides and insecticides to a much greater degree than plants grow in controlled indoor environments.

The establishment of a legal path to market for CBD derived from Hawai'i grown industrial hemp has the potential to improve access to affordable, quality-assured CBD products for consumers and medical cannabis patient at a fraction of their current cost. However, because field-grown industrial hemp plants are highly susceptible to contamination, rigorous testing by state-certified laboratories for the presence of microbial contaminants, heavy metals and pesticides is an imperative. We cannot build a trusted and sustainable hemp sector if we compromise on product quality and safety.

Mahalo for your consideration.

Pan Pacific Ventures, LP
PO Box 1149
Kula, HI 96790



February 18, 2020

To: Representative Sylvia Luke, Chair
Representative Ty. J.K. Cullen, Vice Chair
Members of the House Committee on Finance

From: Chris Cole, Director of Product Development, Maui Grown Therapies

Re: TESTIMONY IN SUPPORT OF HOUSE BILL 2102 HD1 WITH MODIFICATIONS
RELATING TO HEMP PRODUCTS

Maui Grown Therapies is one of eight companies licensed by the Department of Health under Hawai'i Revised Statutes 329D to cultivate, manufacture and dispense medical cannabis and medical cannabis manufactured products to qualifying patients.

Maui Grown Therapies **supports** House Bill 2102 HD1, which establishes much-needed quality control, packaging and labeling requirements for hemp-derived products. However, among its many provisions, HB2101 HD1 clarifies that dispensaries licensed under HRS 329D shall not be prohibited from manufacturing, distributing, and selling 'products that contain hemp, or cannabinoids, extracts, or derivatives from hemp grown in compliance applicable law; provided that

- (1) No licensed entity shall include any hemp product as an ingredient in the licensed entity's manufactured cannabis product without first getting approval from the department'

This language requires dispensaries licensed under HRS 329D to get department approval for products that the department has already approved. As a medical cannabis licensee, Maui Grown Therapies has been cultivating varieties of *Cannabis sativa* that meet the legal definition of industrial hemp (e.g. contain less than .3% THC on a dry weight basis), and including hemp derived material therefrom in manufactured products since August 2017. No risk to the public health has resulted from this practice, because *every batch of medical cannabis and medical cannabis derivative products dispensary licensees produce is subject to mandatory third-party quality control testing for the presence of contaminants and for composition, as well as strict packaging and labeling requirements, as preconditions for sale.*

Indeed, the quality control, packaging and labeling standards dispensary licensees' products must meet go far beyond what is contemplated for hemp products in HD 2102 HD1. Requiring dispensary licensees to obtain department approval to use hemp derived products in their manufacturing process adds unnecessary regulatory costs and complexity to a program that is already thoroughly and effectively regulated – while not in any way improving public health or product safety.

We urge your committee to strike this redundant and costly regulatory provision from HB2102 HD1.

Mahalo for your consideration.

Maui Grown Therapies
44 Pa'a St., Kahului, HI 96732
(808) 866 7576



Maui Grown Therapies
44 Pa'a St., Kahului, HI 96732
(808) 866 7576

HB-2102-HD-1

Submitted on: 2/18/2020 12:15:27 PM

Testimony for FIN on 2/19/2020 4:00:00 PM

Submitted By	Organization	Testifier Position	Present at Hearing
JARED DALGAMOUNI	Hawaiian Choice	Support	No

Comments:

Dear Committee Members,

Thank you for the opportunity to provide testimony today. My name is Jared Dalgamouni and I am the founder of a local CBD manufacturing company called Hawaiian Choice. We are a local business in Hawaii and are a leading Hawaii manufacturer of luxury, super premium CBD products with our products currently carried by over 100 local retailers, plus 50 more on the mainland, Japan, Mexico and Switzerland.

We support the intent of HB2102 strongly, and applaud your efforts to make regulatory progress in this area. Farmers, Manufacturers, and Retailers need a reasonable level of regulation, which we feel this Bill provides.

We have some concerns about the intend of changing the date on this bill to the year 2050, and we understand that this is because there has been some discussion of not "overregulating CBD" and we can assure you that this bill does not do that. In fact, we believe the level described is essential.

As such we warn strongly against delaying the immediate implementation of this Bill because Hawaii's retailers, especially the larger corporate retailers, have been clear with us that out of the abundance of caution they need explicit assurance that CBD is allowed for them to sell. The lack of regulation to date in this area has not provided security for Hawaii's consumers, and has had the effect of keeping larger retailers on the sidelines. This inaction has hurt the expansion of this industry, to the detriment of Hawaii's manufacturers, and by extension the hemp farmers. Adoption by the larger retailers is key to giving credibility to our local brands to "not miss the boat" as a springboard to the National Retailers on the mainland.

As an example, the lack of clarity - in particular the DOH statement of April 26, 2019 and May 1, 2019 - have already prompted a number of civil litigation issues and significantly hurt Hawaii's manufacturers and farmers. There have also been a number of media statements by the DOH to this effect which have been carried in the local news.

<https://health.hawaii.gov/news/files/2019/05/19-027-DOH-Advisory-on-Products-Containing-CBD-and-Safety-002.pdf>
<https://health.hawaii.gov/food-drug/cbd-questions-and-answers/>

Specifically as you may be already aware one of the 329 Licensees has already been sending, via their lawyers, Cease and Desist letters to some of Hawaii's largest retailers claiming those retailers are not allowed to sell CBD products and that only the dispensaries are. This is obviously economically motivated, and has caused some of these retailers to stop selling CBD products whilst they await legislation. This has had a secondary effect of causing disruption, uncertainty, and fear in the secondary market of smaller retailers who look to these larger retailers for example. I understand also that there have been some Mainland CBD companies which have been sending form letters to some of Hawaii's leading spas threatening them with unfounded legal action if they use Hawaiian made products, causing a chill in those larger corporates towards the overall industry. All these are consequences of not regulating CBD and providing explicit assurances to our retailers that Hawaii's CBD products are regulated to a minimum basic standard and are allowed to be grown, manufactured and sold.

It is important that we have a legislative fix implemented immediately before further damage is done, and we ask for the subsequent retraction of these DOH statements and affirmation of HB2102.

Specifically, we have the following requests for amendments:

Page 9, line 6 - we feel this is an unnecessary restriction on this popular form of consumption - and ask that at a minimum there is clarification of what a "food" is - as many edible forms could be construed as "food" including the oil tinctures are made from, gummies, drinks, etc. We ask that this section is struck out entirely or at a minimum clarified.

Page 13, line 13 - we feel that 18 years old is a more appropriate age, especially that over the counter supplements are generally not restricted by age. Cannabinoids, with the exception of THC, are generally deemed non intoxicating and non psychoactive so the intent of this being 21 rather than 18 is unclear. We suggest also that consideration is made for an exception for use by people below this age with the permission of their parents or guardians.

Page 16, line 14 - for the aforementioned reasons, it is essential that this Bill takes effect immediately, and not delayed until the year 2050.

Thank you for your time and attention to this important issue.

Jared Dalgamouni

HB-2102-HD-1

Submitted on: 2/18/2020 1:15:11 PM

Testimony for FIN on 2/19/2020 4:00:00 PM

Submitted By	Organization	Testifier Position	Present at Hearing
Jennifer Carlile	Hawaiian Choice	Support	No

Comments:

Thank you for the opportunity to submit testimony on HB2102.

I am writing in strong support of HB2102 on behalf of Hawaiian Choice, a local CBD manufacturer. I would like to voice my support for all of the testimony submitted by Jared Dalgamouni and will not repeat it here.

There is just one small additional amendment that I hope you will consider.

Page 5, line 10: change “benefits or effects on health” to “benefits or effects on the diagnosis, cure, mitigation, treatment or prevention of any disease.”

I suggest this because term “health” is very broad. According to Merriam-Webster Dictionary, the primary definition of “health” is “the condition of being sound in body, mind or spirit.”

I believe this change would make it clear that CBD companies cannot make any claims relating to diseases and keeps the wording in line with the FDA’s intention.

The wording I am suggesting comes from this FDA article: “FDA is Committed to Sound, Science-based Policy on CBD”

<https://www.fda.gov/news-events/fda-voices-perspectives-fda-leadership-and-experts/fda-committed-sound-science-based-policy-cbd>

Thank you very much for taking the time to read and consider my position in strong support of HB2102.

HB-2102-HD-1

Submitted on: 2/18/2020 3:41:35 PM

Testimony for FIN on 2/19/2020 4:00:00 PM

Submitted By	Organization	Testifier Position	Present at Hearing
Joy Watanabe	ABC Stores	Support	No

Comments:

Aloha,

ABC Stores supports the intent of HB 2102 - Relating to Industrial Hemp derived products.

As noted in the measure there is currently a lot of confusion among retailer and consumers about CBD products. Currently businesses that adhere to the Food and Drug Administration's ("FDA") guidelines are at a commercial disadvantage compared to the many businesses that continue to sell these unregulated products. We support a framework that will create a level playing field and allow consumers to make informed decisions about these products.

The 2018 Farm Bill legalized the sale of CBD from hemp across the USA, but the FDA has failed to regulate it. The FDA maybe working on creating opportunities to research CBD, but this approach will not address the current sale of CBD products within the State of Hawaii in the near future.

Some businesses will continue to sell unregulated products, including food products, if a bill such as HB 2102 is not modified and passed for the regulation of CBD products, including food products. This legal limbo puts both consumers and Hawaii's hemp farms at risk. This bill does offer clear rules for the production and sale of safe hemp and CBD products.

We respectfully request HB 2102 be amended to include the regulation of food products along with other CBD products.

We respectfully also request that HB 2102 include an amendment that will amend the controlled substance law and criminal law to exclude hemp from the definition of marijuana.

Thank you for this opportunity to testify.



www.hawaii hemp farmers association.org
info@hawaii hemp farmers association.org

February 16, 2020

RE: HB 2102 Relating to Hemp Products - **STRONGLY OPPOSED**

Dear Honorable Committee Members,

The Hawaii Hemp Farmers Association is strongly opposed to HB 2102. It will delay and unnecessarily hinder the cannabinoid and hemp product industry for farmers and many Hawaii retailers.

It is a waste of tax payers dollars to set up a complex regulatory system for hemp products ahead of FDA rulings. SB 2050 protects public health and consumers with labeling and independent laboratory testing.

This bill will drive Hawaii customer sales to the internet so they only entities profiting from Hawaii hemp products will be Amazon and mainland hemp farmers and businesses.

We support the model presented by SB 2050 and strongly encourage SB 2050 to incorporate protections for packaging that discourages packaging that may appeal to children. Other concerns can be incorporated into SB 2050.

We object to the application of civil fines for non negligent material violations of the program, the 21 year age limit for purchase of hemp products, and the definition of "hemp" and "hemp product" that does not include flower or leaf material.

Hawaii Farmers support the model that HB 1819 develops to manage the production aspects of the State Hemp Program and support the spirit and intent that rules running the Hawaii program and its products be developed cooperatively between the agencies and farmers to give the Hawaii farmer equal footing with farmers in other states.

Please do not refer HB 2102 to advance through committee.

Respectfully Submitted

Ray Maki

Ray Maki



Vincent Mina
State President

Anabella Bruch
Vice-President
Kauai

Annie M. Alvarado
Treasurer
Maui

David Case
Secretary
Kona, Hawai'i

Eric (Drake)
Weinert, Jr.
East Hawai'i

John Dobovan
Haleakala, Maui

Matthew
VanPaeppeghen
Hana, Maui

Matthew Drayber
K'au, Hawaii

Anabella Bruch
Kauai

Dash Kuhr
Kohola, Hawai'i

Maureen Datta
Kona, Hawai'i

Kaipō Kekona
Lahaina, Maui

Robert (Bobby)
Pahia Mauna
Kahalawai, Maui

Brynn Foster
North Shore, Oahu

Steve Lund
Puna, Hawai'i

Christian
Zuckerman
Wai'anae, Oahu

Vincent Kimura
Waimanalo, Oahu

P.O. Box 99
Wailuku, HI 96793-0099
(808) 800-3974
February 18, 2020

RE: **Oppose** HB 2102 HD 1 Relating to Hemp

Dear Honorable Representatives,

The Hawaii Farmers Union United (HFUU) has 1,300+ members across the state. Our hemp farmers have relayed their strong concerns regarding the likelihood of HB 2102 to severely hamstring or kill the hemp products industry in Hawaii.

We understand that our farmers and Hawaii hemp product manufacturers and retailers are working together to modify SB 2050 to protect public health and the Hawaii hemp industry.

HFUU acknowledges our members' concern that HB 2102 may waste taxpayers dollars by setting up a more complex regulatory system than SB 2050 and ahead of FDA rulings on hemp products.

We urge you to defer and kill HB 2102 HD1 in favor of SB 2050.

HAWAII FARMERS UNION UNITED

Vincent Mina, President

The Hawai'i Farmers Union United and its Chapters are a nonprofit corporation formed under Hawai'i law and Section 501(c)(5) of the Internal Revenue Code. HFUU advocates for the sovereign right of farmers to create and sustain vibrant and prosperous agricultural communities for the benefit of all Hawai'i through cooperation, education and legislation. Because HFUU is an agricultural advocacy organization, donations to it are not tax deductible.



PATIENTS WITHOUT TIME



— helping cannabis patients in Hawaii since 2014.

To: Hawaii State Legislature
House Committee on Finance
30th Legislature, 2019 - 2020

February 16, 2020

Testimony to **OPPOSE** of H.B. 2102

PROPOSED HD1 RELATING TO HEMP PRODUCTS.

Hearing Date: Wednesday, 02-19-20 4:00PM in House conference room 308.

Aloha Chair Sylvia Luke, Vice Chair Cullen, and committee members,

PATIENTS WITHOUT TIME strongly **OPPOSES** H.B. 2102, because adding cannabinoids, like cannabidiol, to cosmetics, or as a food additive, has had limited research. The safety of new nanotechnology transdermal cannabidiol products have not been established. The mixing of ingredients, like Resveratrol, vitamins, vegetable oils, glycerin, propylene glycol, oleic acid, Transcutol, arnica oil, Polysorbate 80, Carbomer 980, and sodium hydroxidemay, ... etc ... , may have unknown adverse interactions.

There has been no research regarding the long-term effects of mixing cannabidiol with patented **cosmetic** ingredients such as Lipoderm products, and other like, Cyclopentasiloxane, Isopropyl Alcohol, or Lidocaine, etc. Even ingredients as seemingly safe as citrus may have unforeseen adverse effects, especially in patients with compromised immune systems, or who are under-going chemotherapy.



PWTmaui.org

For more info email: info@PWTmaui.org

Testimony to **OPPOSE** of H.B. 2102, cont.

The FDA is not aware of any basis to conclude that CBD is **GRAS** among qualified experts for its use in human or animal food. **There is no food additive regulation which authorizes the use of CBD as an ingredient in human food or animal food**, and the agency is not aware of any other exemption from the food additive definition that would apply to CBD. **CBD is therefore an unapproved food additive**, and its use in human or animal food violates the FD&C Act for reasons that are independent of its status as a drug ingredient. <https://www.fda.gov/news-events/press-announcements/fda-warns-15-companies-illegally-selling-various-products-containing-cannabidiol-agency-details>

The FDA warns; “Companies are adding CBD to creams, oils, food and beverages. However, it’s currently illegal for companies to sell CBD-infused food and beverages across state lines and to market any CBD products with health claims the FDA has not evaluated.” <https://www.cnbc.com/2019/11/26/cbd-might-not-be-safe-despite-flood-of-products-fda-warns-consumers.html>

Patents should have a doctor’s recommendation before experimenting with cannabinoids. Cannabinoids, like cannabidiol, are powerful medicines, with known and unknown side-effects. Patients may need tests to monitor liver enzymes, blood pressure, and the effects that CBD may be having on the patient’s other prescription medications. CBD is known to interact with multiple common prescription and OTC medications, such as Coumadin and NSAIDS, methotrexate, Prozac, benzodiazepines, Macrolide antibiotics, heart medications, etc. Utilizing nanotechnology in the formulation of nano CBD products to increase bioavailability and subsequent bioactivity, may cause CBD to pass through the blood brain barrier, and the long term effects are unknown.



Testimony to **OPPOSE** of H.B. 2102, cont.

Hawaii State has failed to stop the widespread erroneous medical advice, and unscrupulous marketing practices of 100's of Hawaii's CBD marketers, instead just turning a blind eye to the outrageously bogus medical claims being made in mass-marketing schemes.

Hawaii State has not been enforcing the State laws against marketing cannabidiol products and is thereby needlessly endangering the health of Hawaii's citizens. As you are aware, Hawaii has a medical cannabis program, where patients that would like to experiment with CBD concentrates, can do so, under doctor's care, with protection from prosecution, provided by the state.

Cannabidiol Enhances the Passage of Lipid Nanocapsules across the Blood-Brain Barrier Both in Vitro and in Vivo. Mol Pharm. 2019 May 6;16(5):1999-2010. doi: 10.1021/acs.molpharmaceut.8b01344. Epub 2019 Mar 22.

There are many unanswered questions about the science, safety, and interactions of CBD products. Therefore, **Hawaii's Medical Cannabis Program, under the administration of Hawaii's Health Department are currently the appropriate entities to regulate the marketing of cannabinoid medicines** to seriously ill patients.

Please, **OPPOSE** this bill, **H.B. 2102**,

Thank you for your kind attention to this vital health and legal issue,

Brian Murphy, Director

PATIENTS WITHOUT TIME



HB-2102-HD-1

Submitted on: 2/17/2020 8:55:51 PM

Testimony for FIN on 2/19/2020 4:00:00 PM

Submitted By	Organization	Testifier Position	Present at Hearing
Mariner Revell	Irie Hawaii Stores	Oppose	No

Comments:

Why would anyone restrict open access to CBD? Show me one person that has overdosed from CBD or has had a severe negative reaction to CBD! Where is the proof that CBD is harmful and should only be sold by a dispensary or pharmacy? Furthermore why restrict hemp products from Children? There are many Hemp food products on the market! Are children also going to be restricted from using products made of hemp? Stop protecting the interests of Big Pharma!



February 18, 2020

RE: **OPPOSED** to HB 2102 HD 1 Relating to Hemp

Aloha, Honorable Representatives,

We strongly oppose HB 2102 HD1. It will hamstring or kill the hemp products industry in Hawaii, which means we farmers will be put out of business.

SB 2050 protects public health with labeling and independent laboratory testing. SB 2050 can be amended to address concerns regarding packaging for children and cigarettes.

HB 2102 HD1 will waste taxpayers money by establishing a regulatory system ahead of Federal rules being issues and a framework beyond what is immediately needed and provided for in SB 2050.

We urge you to defer this bill and let it die.

Sincerely,

Gail Byrne Baber

Gail Byrne Baber
Co-founder

Clarence Baber

Clarence Baber
Co-founder

U.S. Hemp Roundtable

502.319.2358 | 100 M Street, S.E., Suite 600, Washington, DC 20003 | info@hempsupporter.com

February 18, 2020

Representative Sylvia Luke
Chair, House Committee on Finance

Chair Luke, Vice Chair Cullen, and member of the House Committee on Finance:

Thank you for the opportunity to provide testimony offering comments with concerns on HB 2102 HD1 RELATING TO HEMP PRODUCTS. The measure would require labels on hemp products; prohibit unwarranted health-related statements about hemp products; establish standards for hemp product manufacturers; prohibit the manufacture or sale of any food into which a hemp product has been added; prohibit the sale of hemp products designed to appeal to children; establish that a product shall not be considered adulterated or misbranded solely by the inclusion of hemp with certain exceptions; clarify that a licensed medical cannabis dispensary is not prohibited from manufacturing, distributing, or selling products that contain hemp, or cannabinoids, extracts, or derivatives from hemp, subject to certain conditions; prohibit the sale of hemp products to persons under twenty-one years of age; and require DOH to report to the legislature.

The U.S. Hemp Roundtable is a coalition of leading companies and organizations committed to safe hemp and CBD products. We proudly represent the industry's major national grassroots organizations, and are leading the way forward for hemp and CBD products through education and action. We do not view industrial hemp derived products as medication, and believe that the most effective way to realize the potential of the industrial hemp market and allow for safe and regulated CBD products in the market is to establish the right conditions for the market to flourish.

Since the passage of the federal Farm Bill in 2018, which effectively legalized the sale of cannabidiol products from the commercial cultivation of hemp, more than sixteen thousand hemp growers have emerged throughout the United States. The hemp industry across the country has grown rapidly, and hemp-derived products including cannabidiol are used by a wide range of consumers. In Hawaii, there are currently over 30 registered hemp growers under the Industrial

Hemp pilot program.

It is expected that the Food and Drug Administration will eventually use its authority to regulate hemp-derived products. However, the only enforcement action that the FDA has taken to date is to issue warning letters against improper disease remediation claims made by food and supplement companies. The Hawaii Department of Health has adhered to guidance from the FDA that provides that food, beverage, or cosmetic products that contain cannabidiol are adulterated and therefore prohibited under law. Despite this suggested prohibition, cannabidiol products continue to be sold across Hawaii, with no regulatory oversight. Given the time expected for the FDA to act, other states have considered and enacted their own regulatory frameworks for hemp-derived cannabidiol. We believe that it is prudent for Hawaii to also do so, and support the approach outlined in HB 2102.

We believe that HB 2102 HD1 has deviated away from the intent of the original bill. Under the HD1, Industrial Hemp derived CBD products would be prohibited from food products, limited to persons above the age of twenty-one, and place the adoption of rules on the Department of Health. It is our view that the proposed HD1 of HB 2102 would continue to promulgate the existing on-line and unregulated marketplaces that exists today, without any protections for consumers. We would recommend that the legislature consider the providing a more market-oriented approach and allow for the industry to create a viable market of regulated industrial hemp derived products which was envisioned in the original draft of HB 2102.

Notwithstanding the above concerns, we would respectfully ask that the legislature continue to move this measure forward and allow for all the interested stakeholders the opportunity for continued discussion.

Thank you for the opportunity to submit testimony on this measure.

HB-2102-HD-1

Submitted on: 2/18/2020 2:35:54 PM

Testimony for FIN on 2/19/2020 4:00:00 PM

Submitted By	Organization	Testifier Position	Present at Hearing
Tasia Collier	Individual	Support	No

Comments:

To whom it may concern,

I support HB 2102 fully. This is a good thing for manufacturers and consumers. Having clearly printed labels and eliminating unsubstantiated health claims will allow consumers to feel safe. Making sure there are safety measures to protect children/minors adds another layer of protection and security.

Respectfully,

Tasia Collier

HB-2102-HD-1

Submitted on: 2/18/2020 2:06:37 PM

Testimony for FIN on 2/19/2020 4:00:00 PM

Submitted By	Organization	Testifier Position	Present at Hearing
pua	Individual	Support	No

Comments:

HB-2102-HD-1

Submitted on: 2/17/2020 10:29:38 PM

Testimony for FIN on 2/19/2020 4:00:00 PM

Submitted By	Organization	Testifier Position	Present at Hearing
John Calvert	Individual	Support	No

Comments:

Aloha Members of the Committee,

My name is John Calvert and I'm a hemp licensee and small farmer in Puna district, Big Island. I am growing CBD hemp using the horticultural method, in a greenhouse.

HB2102 appears to be consistent with a new [bi-partisan bill in Congress, H.R.5587](#), which would allow hemp-derived CBD to be lawfully marketed as a dietary supplement. I think there's a very good chance the Senate will pass a version of this legislation in 2020, with Leader Mitch McConnell representing the vanguard hemp farmers of Kentucky.

I am in full support of this well-written legislation, HB2102, in its entirety without any amendments.

mahalo nui loa,
John Calvert

February 18, 2020

TO: Representative Sylvia Luke, Chair
Representative Ty Cullen, Vice Chair
Members of the House Finance Committee

FROM: Michael Backes, Cannabinoid Researcher, Author, Consultant

Re: TESTIMONY IN SUPPORT OF HB2102 HD1

RELATING TO HEMP PRODUCTS

Thank you for the opportunity to testify in support of HB2102 HD1. I am a medical cannabis researcher, author of *Cannabis Pharmacy*, educator, and cannabis policy consultant with clients in Hawai'i and abroad. Since 2008, I've been an advocate for Project CBD, a nonprofit dedicated to promoting and publicizing research into the medical uses of cannabidiol. It was my pleasure to participate in a briefing on CBD at the invitation of Senator Baker and Representative Mizuno in this building last September.

Since the September legislative briefing, the FDA updated its public advisory¹ for CBD to confirm the prescription drug Epidiolex is the only approved CBD product in the United States. The FDA further clarified that it is illegal to market CBD as a dietary supplement. After reviewing limited CBD data, the FDA concluded the health risks were significant enough to issue a consumer advisory against taking CBD. The FDA is concerned that people mistakenly believe that CBD "can't hurt," when in fact it can. Very few consumers are aware of the potential health risks associated with using CBD products including interactions between CBD and several commonly prescribed drugs.

The FDA has also continued to issue warning letters to companies for illegally selling CBD-containing products in violation of the Federal Food, Drug, and Cosmetic Act (FD&C Act). Misleading, unproven, and false claims about CBD products can lead consumers to delay urgent medical care or to substitute CBD products for needed medication.

A study led by Marcel Bonn-Miller² published in the *Journal of American Medicine* in 2017, tested the contents of 84 different CBD products sold online and found that nearly 70 percent were inaccurately labeled; THC was detected in 18 of these 84 products. Other surveys have yielded similar results.

¹ <https://www.fda.gov/consumers/consumer-updates/what-you-need-know-and-what-were-working-find-out-about-products-containing-cannabis-or-cannabis>

² Bonn-Miller MO, Loflin MJE, Thomas BF, Marcu JP, Hyke T, Vandrey R. Labeling Accuracy of Cannabidiol Extracts Sold Online. *JAMA*. 2017;318(17):1708-1709. doi:10.1001/jama.2017.11909

Confusion about these products stems from the misperception that the 2018 Federal Farm Bill “legalized” CBD. When Congress passed the bill, it established a legal category of cannabis known as hemp, defined as containing no more than 0.3% THC. However Congress explicitly preserved the FDA’s authority to regulate CBD-containing products to ensure they’re safe and that claims made about them are valid. Under current law, CBD is permitted in food or dietary supplements *only* if the FDA issues a regulation allowing its use. Unfortunately, FDA regulations have yet to be issued.

In the absence of explicit FDA regulation, state and regional governments need to step in to protect public health. I’ve observed state regulatory efforts through the nation.

In May 2018, the Centers for Disease Control (CDC) published its summary³ of a case in Utah when 52 people were sickened by a product named *Yolo CBD Oil*. The top three reported symptoms were altered mental states, nausea or vomiting, and seizures or shaking. The product label contained no information about the manufacturer, or ingredients. The product was tested by the Utah Public Health Laboratory and the Utah Department of Public Safety Crime Laboratory and found to contain a synthetic cannabinoid, 4-cyano CUMYL-BUTINACA (4-CCB), but no CBD. As a result, the CDC recommended, “States should consider regulating products labeled as CBD and establishing surveillance systems for illness associated with products labeled as CBD to minimize the risk for this emerging public health threat.”

In 2018, the Utah State Legislature passed HB130, the Cannabidiol Product Act⁴ that authorizes the cultivation, production, and possession of hemp and the sale and use of cannabidiol products under certain circumstances; grants various state agencies rulemaking authority and requires all CBD products to be registered with the state and provide lab samples and consumer data. The measure also directs the state to randomly test CBD products for potency and contaminants.

Like Utah’s example, HB2102 HD1 takes a significant step toward safeguarding public health by providing for testing of hemp-derived CBD throughout Hawai‘i. Unlike Utah, Hawai‘i has already established considerable institutional capacity focused on patient welfare, quality-assured products and public safety since establishing the medical cannabis dispensary system in 2015. This system includes certification and inspection of independent testing labs monitored by the Hawai‘i Department of Health, State Labs Division.

Because this infrastructure is applied to the emerging industrial hemp sector, I urge passage of HB2102 HD1.

³ Horth RZ, Crouch B, Horowitz BZ, et al. *Notes from the Field: Acute Poisonings from a Synthetic Cannabinoid Sold as Cannabidiol — Utah, 2017–2018.* MMWR Morb Mortal Wkly Rep 2018;67:587–588. DOI: <http://dx.doi.org/10.15585/mmwr.mm6720a5>

⁴ <https://le.utah.gov/~2018/bills/static/SB0130.html>

HB-2102-HD-1

Submitted on: 2/17/2020 8:21:49 PM

Testimony for FIN on 2/19/2020 4:00:00 PM

Submitted By	Organization	Testifier Position	Present at Hearing
VALENTINO MIRANDA-KEPA	Individual	Oppose	No

Comments:

HB-2102-HD-1

Submitted on: 2/17/2020 9:03:52 PM

Testimony for FIN on 2/19/2020 4:00:00 PM

Submitted By	Organization	Testifier Position	Present at Hearing
Jericho Tobin	Individual	Oppose	No

Comments:

HB-2102-HD-1

Submitted on: 2/17/2020 9:09:59 PM

Testimony for FIN on 2/19/2020 4:00:00 PM

Submitted By	Organization	Testifier Position	Present at Hearing
Eric Heaukulani	Individual	Oppose	No

Comments:

HB-2102-HD-1

Submitted on: 2/17/2020 9:30:33 PM

Testimony for FIN on 2/19/2020 4:00:00 PM

Submitted By	Organization	Testifier Position	Present at Hearing
Monique gunn	Individual	Oppose	No

Comments:

HB-2102-HD-1

Submitted on: 2/17/2020 9:44:50 PM

Testimony for FIN on 2/19/2020 4:00:00 PM

Submitted By	Organization	Testifier Position	Present at Hearing
Theresa Revell	Individual	Oppose	No

Comments:

Honorable Representatives:

I strongly oppose HB2102. Hemp is a plant that has multiple uses, to treat it as anything other than that is wrong. Please vote against HB2102.

Respectfully submitted,

Theresa Revell

HB-2102-HD-1

Submitted on: 2/17/2020 9:57:09 PM

Testimony for FIN on 2/19/2020 4:00:00 PM

Submitted By	Organization	Testifier Position	Present at Hearing
Naomi Muronaka	Individual	Oppose	No

Comments:

HB-2102-HD-1

Submitted on: 2/17/2020 10:00:18 PM

Testimony for FIN on 2/19/2020 4:00:00 PM

Submitted By	Organization	Testifier Position	Present at Hearing
Louis Bauguess	Individual	Oppose	No

Comments:

Aloha,

I oppose HB2102. Hemp products help people with all their uses.

Mahalo,

Louis Bauguess

HB-2102-HD-1

Submitted on: 2/18/2020 8:05:46 AM

Testimony for FIN on 2/19/2020 4:00:00 PM

Submitted By	Organization	Testifier Position	Present at Hearing
Andy Takaaze	Individual	Oppose	No

Comments:

I oppose any unnecessary taxes and or regulations on products already being sold safely on the free market. STOP over regulation, let the market determine product viability.

HB-2102-HD-1

Submitted on: 2/18/2020 8:34:10 AM

Testimony for FIN on 2/19/2020 4:00:00 PM

Submitted By	Organization	Testifier Position	Present at Hearing
ellen benton	Individual	Oppose	No

Comments:

HB-2102-HD-1

Submitted on: 2/18/2020 8:34:27 AM

Testimony for FIN on 2/19/2020 4:00:00 PM

Submitted By	Organization	Testifier Position	Present at Hearing
ASHLEY MATTOS	Individual	Oppose	No

Comments:

HB-2102-HD-1

Submitted on: 2/18/2020 9:05:40 AM

Testimony for FIN on 2/19/2020 4:00:00 PM

Submitted By	Organization	Testifier Position	Present at Hearing
natalea mikami	Individual	Oppose	No

Comments:

HB-2102-HD-1

Submitted on: 2/18/2020 9:09:50 AM

Testimony for FIN on 2/19/2020 4:00:00 PM

Submitted By	Organization	Testifier Position	Present at Hearing
dillon rellez	Individual	Oppose	No

Comments:

I oppose this bill because regular businesses should be able to sell hemp that is tested and has all of its information, that being said all hemp products should be properly labeled and no one should take any product without consulting their doctor. Thank you for your time.

HB-2102-HD-1

Submitted on: 2/18/2020 9:30:08 AM

Testimony for FIN on 2/19/2020 4:00:00 PM

Submitted By	Organization	Testifier Position	Present at Hearing
HANALEI BENN	Individual	Oppose	No

Comments:

Don't take our rights away from a natural Hemp product. It wasnt a problem until it was alot easier to get. CBD is a great product that everyone should have a choice to.

HB-2102-HD-1

Submitted on: 2/18/2020 9:39:03 AM

Testimony for FIN on 2/19/2020 4:00:00 PM

Submitted By	Organization	Testifier Position	Present at Hearing
Hoku	Individual	Oppose	No

Comments:

HB-2102-HD-1

Submitted on: 2/18/2020 11:09:57 AM

Testimony for FIN on 2/19/2020 4:00:00 PM

Submitted By	Organization	Testifier Position	Present at Hearing
jonah	Individual	Oppose	No

Comments:

HB-2102-HD-1

Submitted on: 2/18/2020 3:05:55 PM

Testimony for FIN on 2/19/2020 4:00:00 PM

Submitted By	Organization	Testifier Position	Present at Hearing
Richard	Individual	Oppose	No

Comments:

February 9, 2020

Richard Bodien
KOKOIKI BRANDS LLC.
POB 198900
Hawi, Hawaii 96719
808 889 1282

RE: Opposition to HB2103 - STRONGLY OPPOSED

Dear Honorable Representatives,

I own several small businesses in Kohala on Hawaii Island. The State licenses me to sell liquor and tobacco products with known health and public safety risks that include mental impairment, overdose, abuse, violence, and death, because it wants the tax revenue.

I have been engaged in studying and selling CBD for over four years. In those four years I have never seen an example of mental impairment abuse, violence, or death associated CBD use. I have met a lot of homeless people and addicts and alcoholics, but I have never met one in this condition because of CBD use. What I have seen is people get off opiates, get some sleep, relieve their tired muscles, and treat their anxiety and depression without pharmaceuticals, synthetics, or illegal drugs.

I most recently created a company to process, package and market hemp flower. Here's the joke: my best hemp product is "Hawaiian Haze" grown in the Hudson Valley of New York.

I have some serious questions regarding HB2102.

Is this about Public Safety? Or is this an effort to channel the CBD sales in Hawaii to established medical marijuana dispensary corporations?

If this is a public safety issue, then fine, let's see the stats and let's crack down. But if this is an effort to monopolize the sale of these products in Hawaii, it will fail dramatically, and simply push sales online. {"Hmm, should I drive fifty miles or buy it on Amazon and have it delivered in two days?"}

One the one hand, it may be completely harmless and helpful and we could allow everyone to grow hemp and create an industry to process it. This would be a very ecologically intelligent and sustainable choice. Or, it may be so dangerous that we should prevent everyone from doing anything with it. But why, under the guise of confusion and uncertainty, single out one type of producer and one distribution methodology as legitimate?

PEOPLE AND ANIMALS

Our working and older populations live in pain, suffer great anxieties, and can't sleep. They want relief. They are not getting the relief they seek from pharmaceuticals and opiates. Do we want to deprive them of access to harmless products that provide effective relief and improve their overall well being?

Our pets and animals also suffer pain and anxiety, and they too benefit from access to CBD products. Are we going to force them, too, back to using pharmaceuticals and opiates and suffering their side effects.

Are we going to make people in rural areas drive inordinate distances to acquire pain relieving and health improving products? Is your elderly auntie or disabled uncle going

to drive fifty to a hundred miles round trip to purchase these products at a marijuana dispensary?

Will this law protect consumers, or just make their lives more inconvenient, expensive, and miserable?

PUBLIC HEALTH AND SAFETY: “The legislature also finds that despite efforts to educate the public about the risks of cannabidiol . . . “

What are those risks? If CBD is as dangerous as this bill asserts, it must be too dangerous to sell anywhere

Is this an emergency? Has there ever been a single hemp or CBD overdose in the State of Hawaii?

Are the ERs crowded with cases of CBD poisoning?

Are there people on the streets homeless because of their CBD abuse? Have we seen an increase in Disorderly Conduct from hemp or CBD use?

Are there people swarming rehab because of CBD abuse? Are there people dying from CBD use? Are people getting addicted?

Are we going to stifle emergent health solutions that don't come with addiction or the side effects of synthetic “medicines”?

BUSINESS

Does this bill advance the health and happiness of the state, or condense the market into the hands of already privileged corporations?

Was this bill written by Amazon? Do you really want to give more business to Amazon? Do we really want to drive CBD purchases in our state to online shops from the mainland? Is your auntie going to drive fifty miles round trip to go to a marijuana dispensary, or have it shipped?

Does Hawaii really want to once again throw away an opportunity for small farms and businesses to thrive?

Or could our state prosper from increased consumer interest in another branded Hawaiian specialty cash crop, similar to Kona coffee, and grown and crafted artisanally, instead of industrially?

Cannabis and hemp are already commodities throughout the world. Does Hawaii want to give what opportunity is left here to the few monied interests controlling local dispensaries?

Does the failure of the Canadian and California models of regulation, and the implosion of hemp prices nationally, provide any indication of the quality and price problems that regulation creates?

—

I strongly oppose SB 2274 because it creates excessive and unnecessary regulation for the sole purpose of monopolizing the industry into the hands of marijuana dispensaries. This bill will essentially destroy CBD usage, small hemp farmers, and those small businesses who have invested in this market.

The State of Hawaii should establish a free and open market for cannabinoid (CBD) products at all levels: farming, product development, distribution, and sales. Let our farmers grow, let's get some processors and producers rolling, and let our retailers bloom, or see this local opportunity wash away in a sea of online sales by national brands.

At this same time, we need to begin protecting our agricultural property. Only hemp that is grown in Hawaii should be used in products that use labels or marketing materials and strategies that use the words "Hawaiian hemp" or other place or Ahupuaa names in Hawaii, such as "Maui hemp", or references to Hawaiian culture such as "hula" in association with the word "hemp".

In conclusion, CBD and Hemp should be treated like coffee, macadamia nuts, and fruit, and the State should be strategically invested in promoting the hemp industry for the health, happiness, and sustainable prosperity it offers to the State of Hawaii.

Respectfully submitted,

Richard

Kokoiki Brands

Hawi, Hawaii

LATE

HB-2102-HD-1

Submitted on: 2/18/2020 5:45:12 PM

Testimony for FIN on 2/19/2020 4:00:00 PM

Submitted By	Organization	Testifier Position	Present at Hearing
Steve Sakala	Honaunau Farm and Wellness Retreat	Support	No

Comments:

Aloha Honorable Committee Members,

Thank you for taking the time to allow this late testimony. As a farmer and full-time business owner I often do not get to reading emails about committee meetings until later in the day. I'm writing to you today in **strong support** of Bill **HB2102** with **amendments**.

I have been involved in the cannabis industry for over 20 years and have been working with CBD for over a decade. I was also one of the recipients of the HDOA RPF funds to research and grow the first hemp plots here in Hawaii. During my time in the industry working with CBD, and the other cannabinoids, I have found tremendous benefits for myself, friends and family. I also believe strongly that hemp can be a part of the successful emergence of diversified agriculture in Hawaii's economy.

I urge this legislative body to find the right balance of needed regulation, protection for the consumer and market support. These hemp products are already widely available countrywide. Over regulation would just push the consumer to online sales. This would also force the local hemp farmers and manufacturers to miss out on important lucrative segments of the market.

The World Health Organization (WHO) released a two year study in the fall of 2017 that stated: "naturally occurring CBD is safe and well tolerated in humans (and animals), and is not associated with any negative public health effects".

I would like to request this legislation be implemented within 3 months of passing. Additional suggestions for amendments follow.

Page 9, line 6 - Please strike this. This is an unnecessary restriction on this popular form of consumption - Adding CBD to a chocolate bar would, for example, increase the sales of locally made products that include cannabinoids. At a minimum, there needs to be a clarification of what "food" is. Tinctures, oils, honey should not be labeled as food for the purpose of delivering cannabinoids. This section is struck out entirely or at a minimum clarified.

Page 13, line 13 - 16 years old is a more appropriate age, especially that over the counter supplements are generally not restricted by age. Cannabinoids, with the exception of THC, are generally deemed non-intoxicated and non-psychoactive so the intent of this being 21 rather than 16 is unclear. We suggest also that consideration is made for an exception for use by people below this age with the permission of their parents or guardians.

Thank you again for your service and for receiving this late testimony. I strongly urge you to amend HB2102 for the benefit of Hawai'i farmers, manufacturers, and consumers.

Mahalo nui,

Steve Sakala



LATE

February 18, 2020

To: The Honorable Sylvia Luke, Chair
House Committee on Finance
From: Eric Steenstra, President, Vote Hemp

Subject: OPPOSITION to HB 2102 – hemp products: Hearing: February 19 at 4:00 pm

Chairwoman Luke and committee members;

My name is Eric Steenstra and I am the president of Vote Hemp, the nations leading non-profit advocacy group working to bring back hemp as a commercial crop and to grow the global market for hemp products. Today I am writing you in opposition to HB 2102.

HB 2102 will update Hawaii law to require labels on hemp products, prohibit unwarranted health-related statements about hemp products, establish standards for hemp product manufacturers and prohibits the sale of hemp products to persons under twenty-one years of age among other provisions. Unfortunately there are serious flaws with this legislation as drafted.

The bill defines “hemp product” overly broadly to include “any part of the hemp plant” which means that these regulations would apply to the sale of hemp seed oil sold as a supplement for example as well any body care or cosmetic product made from hemp seed oil.

Furthermore the bill would create a special requirement limiting the sale of “hemp products” as defined only to those who are 21 or older. No other supplements, topicals or body care products on the market face this restriction and therefore it is an unfair and unnecessary restriction on trade in hemp products and limitation on consumer access to hemp products.

For these reasons, I urge you NOT to pass HB 2102.

Sincerely,

Eric Steenstra

COMMUNITY ALLIANCE ON PRISONS

P.O. Box 37158, Honolulu, HI 96837-0158

Phone/E-Mail: (808) 927-1214 / kat.caphi@gmail.com



COMMITTEE ON FINANCE

Rep. Sylvia Luke, Chair

Rep. Ty Cullen, Vice Chair

Wednesday, February 19, 2020

4:00 pm – Room 308

LATE

OPPOSE HB 2102 HD1; SUPPORT for ORIGINAL HB 2102 - HEMP PRODUCTS

Aloha Chair Luke, Vice Chair Cullen and Members of the Committee!

My name is Kat Brady and I am the Coordinator of Community Alliance on Prisons, a community initiative promoting smart justice policies in Hawai`i for more than two decades. This testimony is respectfully offered on behalf of the families of **JAMES BORLING SALAS, ASHLEY GREY, DAISY KASITATI, JOEY O`MALLEY, JESSICA FORTSON AND ALL THE PEOPLE WHO HAVE DIED UNDER THE "CARE AND CUSTODY" OF THE STATE**, including the eleven (11) people that we know of, who have died in the last six (6) months. We also remind the committee of the approximately 5,200 Hawai`i individuals living behind bars or under the "care and custody" of the Department of Public Safety on any given day, and we are always mindful that more than 1,200 of Hawai`i's imprisoned people are serving their sentences abroad thousands of miles away from their loved ones, their homes and, for the disproportionate number of incarcerated Kanaka Maoli, far, far from their ancestral lands.

The original HB 2102 requires labels on hemp products; prohibits unwarranted health-related statements about hemp products; establishes standards for hemp food product manufacturers. It also establishes that a product shall not be considered adulterated or misbranded solely by the inclusion of hemp. It clarifies that a licensed medical cannabis dispensary is not prohibited from manufacturing, distributing, or selling products that contain hemp, or cannabinoids, extracts, or derivatives from hemp.

Community Alliance on Prisons supports the original version of this bill. In our view, the HD1 amendments create an unenforceable situation.

Hemp has been around for thousands of years. This bill basically says that people suffering from conditions that could be relieved by salve or other hemp products would no longer find them available. What about parents of children suffering with a variety of ailments that hemp products could help?

Community Alliance on Prisons respectfully asks the committee to restore the original version of this bill.

Mahalo for this opportunity to testify.

LATE

HB-2102-HD-1

Submitted on: 2/19/2020 9:37:01 AM

Testimony for FIN on 2/19/2020 4:00:00 PM

Submitted By	Organization	Testifier Position	Present at Hearing
Wendy Arbeit	Individual	Oppose	No

Comments:

I strongly oppose this bill.

Hemp would be an excellent replacement on agricultural lands formerly used for sugarcane and would bioremediate the soil. FDA has made legal hemp seed-derived food ingredients, hulled hemp seed, hemp seed protein powder, and hemp seed oil to market in human foods. Since the psychoactive component of cannabis is exceedingly low, it's virtually impossible for anyone to get "high" off it, so there is no reason to prohibit the sale of hemp products to anyone under the age of 21. Reject this bill and instead support the growing and use of industrial hemp.

LATE

HB-2102-HD-1

Submitted on: 2/19/2020 10:33:28 AM

Testimony for FIN on 2/19/2020 4:00:00 PM

Submitted By	Organization	Testifier Position	Present at Hearing
Randi D	Individual	Oppose	No

Comments:

LATE

HB-2102-HD-1

Submitted on: 2/19/2020 12:08:54 PM

Testimony for FIN on 2/19/2020 4:00:00 PM

Submitted By	Organization	Testifier Position	Present at Hearing
Lena Mochimaru	Individual	Oppose	No

Comments:

“And now, after years of major change for US agriculture and industry, real investment in this versatile crop stands to significantly elevate our economy and quality of life for generations to come.

The idea of upping hemp production is already common ground politically. As farmers have faced water shortages, unstable markets, and punishing seasonal conditions, communities around the country have pressured lawmakers to help them restore US agriculture with more profitable, sustainable plants.”

Hemp is not a drug we don't need these heavy restrictions. Let's create a self sustainable economic opportunity for Hawaii and it's people.

<https://www.google.com/amp/s/www.forbes.com/sites/janetwburns/2018/09/30/we-should-be-pouring-time-and-money-into-hemp-period/amp/>

LATE

HB-2102-HD-1

Submitted on: 2/19/2020 2:51:58 PM

Testimony for FIN on 2/19/2020 4:00:00 PM

Submitted By	Organization	Testifier Position	Present at Hearing
Stephanie Austin	Individual	Oppose	No

Comments:

This bill is in desperate need of revision, as excludes harmless hemp products, and increases barriers for the creation of a profitable agricultural crop for Hawaii!

LATE

HB-2102-HD-1

Submitted on: 2/19/2020 2:51:58 PM

Testimony for FIN on 2/19/2020 4:00:00 PM

Submitted By	Organization	Testifier Position	Present at Hearing
Stephanie Austin	Individual	Oppose	No

Comments:

This bill is in desperate need of revision, as excludes harmless hemp products, and increases barriers for the creation of a profitable agricultural crop for Hawaii!

LATE

HB-2102-HD-1

Submitted on: 2/19/2020 3:54:21 PM

Testimony for FIN on 2/19/2020 4:00:00 PM

Submitted By	Organization	Testifier Position	Present at Hearing
Michelle Cabalse	Individual	Oppose	No

Comments:

LATE

HB-2102-HD-1

Submitted on: 2/19/2020 4:33:16 PM

Testimony for FIN on 2/19/2020 4:00:00 PM

Submitted By	Organization	Testifier Position	Present at Hearing
Brittany Neal	Individual	Oppose	No

Comments:

I am a Registered Nurse and Big Island hemp farmer. I believe this bill would be detrimental to the hemp industry in Hawaii. I would like to see this bill killed. Thank you for your time and consideration.

Sincerely,

Brittany Neal MSOM, BSN, RN

LATE

HB-2102-HD-1

Submitted on: 2/19/2020 4:38:43 PM

Testimony for FIN on 2/19/2020 4:00:00 PM

Submitted By	Organization	Testifier Position	Present at Hearing
Brent Neal	Individual	Oppose	No

Comments: